,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-06-13 02:30:00,St. Jude Medical Inc. ( STJ ) has won the U.S. Food and Drug Administration (FDA) approval for its Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).,0.9435951709747314,0.016543639823794365,0.039861198514699936,positive,0.9270515441894531
1,2013-06-13 02:30:00,The devices received CE Mark approval in May 2013.,0.28934603929519653,0.00691970344632864,0.703734278678894,neutral,0.2824263274669647
2,2013-06-13 02:30:00,The advanced devices from the company's Cardiac Rhythm Management (CRM) business incorporate unique features that are capable of delivering high-voltage treatment to patients with heart failure.,0.39767229557037354,0.007875379174947739,0.5944523215293884,neutral,0.3897969126701355
3,2013-06-13 02:30:00,"St. Jude is a pioneer in providing a low-friction coating on the ICD device instead of the lead, that helps lower the risk of lead-to-can abrasion.",0.588582456111908,0.013916111551225185,0.3975014388561249,positive,0.5746663212776184
4,2013-06-13 02:30:00,"According to the American Heart Association, there are about 5 million heart failure patients in America, with 550,000 new cases diagnosed every year.",0.04680003225803375,0.04098642244935036,0.9122135043144226,neutral,0.005813609808683395
5,2013-06-13 02:30:00,"ICDs are used to treat abnormal heart rates, which might lead to sudden cardiac deaths (SCD).",0.062319088727235794,0.04626047611236572,0.8914204835891724,neutral,0.01605861261487007
6,2013-06-13 02:30:00,"In the U.S., roughly 325,000 die due to SCD, annually.",0.04408309981226921,0.6744720339775085,0.28144487738609314,negative,-0.6303889155387878
7,2013-06-13 02:30:00,The CRT-D device is used to resynchronize heartbeat in patients with heart failure and provide back up support for SCD.,0.26499155163764954,0.00824440736323595,0.7267640829086304,neutral,0.25674715638160706
8,2013-06-13 02:30:00,St. Jude's core CRM division is still underperforming.,0.020944423973560333,0.9639315009117126,0.015124112367630005,negative,-0.9429870843887329
9,2013-06-13 02:30:00,Revenues from the CRM division fell 8% year over year in the first quarter of 2013.,0.01768123358488083,0.9733211398124695,0.008997714146971703,negative,-0.9556398987770081
10,2013-06-13 02:30:00,"The beleaguered ICD market, as reflected by sustained implant volume pressure, continues to hurt CRM results.",0.01937047950923443,0.9679557085037231,0.012673824094235897,negative,-0.9485852122306824
11,2013-06-13 02:30:00,ICD sales declined 5% in the first quarter but we believe that market trends will stabilize soon.,0.042124126106500626,0.9188238382339478,0.039051953703165054,negative,-0.876699686050415
12,2013-06-13 02:30:00,"St. Jude is currently trying to solve manufacturing and quality systems-related problems at its Sylmar facility, which manufactures the highly controversial Riata ST Optim and Durata leads.",0.09993212670087814,0.777308464050293,0.12275944650173187,negative,-0.6773763298988342
13,2013-06-13 02:30:00,The company received a warning letter from the FDA in Jan 2013.,0.08947332948446274,0.4359341859817505,0.4745924770832062,neutral,-0.34646084904670715
14,2013-06-13 02:30:00,"The FDA is concerned that the newer generation high-voltage Durata leads might face the same problem as the Riata leads, which the company recalled in 2011 due to potential risk of serious injury or deaths.",0.027947265654802322,0.927008330821991,0.04504433646798134,negative,-0.8990610837936401
15,2013-06-13 02:30:00,"However, a recent research conducted by renowned health science research institute Population Health Research Institute (PHRI) demonstrated that St. Jude's Durata and Riata ST Optim ICD leads are safe and reliable.",0.8371824026107788,0.016552137210965157,0.14626552164554596,positive,0.8206302523612976
16,2013-06-13 02:30:00,"Amid several downsides, the approval from the U.S. regulatory body should further boost physician confidence in St. Jude's technologically advanced product portfolio.",0.9517524242401123,0.01999763585627079,0.02824990078806877,positive,0.9317547678947449
17,2013-06-13 02:30:00,"New products from the CRM division should drive top-line growth for St. Jude, once the issue regarding the warning letter is resolved.",0.8816018104553223,0.01271867100149393,0.1056794598698616,positive,0.8688831329345703
18,2013-06-13 02:30:00,St. Jude has a Zacks Rank #3 (Hold).,0.12695863842964172,0.038763195276260376,0.8342781066894531,neutral,0.08819544315338135
19,2013-06-13 02:30:00,"Other medical stocks such as Haemonetics ( HAE ), Atricure ( ATRC ) and Baxano Surgical ( BAXS ) warrant a look.",0.07292371243238449,0.00660555949434638,0.9204707741737366,neutral,0.06631815433502197
20,2013-06-13 02:30:00,"HAE carries a Zacks Rank #1 (Strong Buy), while the other two carry a Zacks Rank #2 (Buy).",0.20860877633094788,0.01631171815097332,0.7750794887542725,neutral,0.1922970563173294
21,2013-06-13 02:30:00,To read this article on Zacks.com click here.,0.01796119473874569,0.019245078787207603,0.9627937078475952,neutral,-0.001283884048461914
22,2013-06-13 02:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
